<p>财富联盟顾问集团有限公司在最近向证券交易委员会提交的文件中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股增加了 30.1%。该机构投资者在本季度购买了 3,047 股后，持有该公司 13,161 股股票。财富联盟顾问集团有限公司在艾伯维的持股在最近的报告期末价值为 2,443,000 美元。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也买卖了 ABBV 的股票。布莱顿琼斯有限公司在第四季度将其在艾伯维的股份提高了 17.4%。布莱顿琼斯有限公司目前拥有 22,912 股该公司的股票，价值为 4,072,000 美元，此前在上个季度又收购了 3,401 股。Revolve Wealth Partners LLC 在第四季度将其在艾伯维的股份提高了 72.7%。Revolve Wealth Partners LLC 目前拥有 7,279 股该公司的股票，价值为 1,294,000 美元，此前在上个季度又收购了 3,064 股。西门子基金投资有限公司在第四季度将其在艾伯维的股份提高了 197.6%。西门子基金投资有限公司目前拥有 179,440 股该公司的股票，价值为 32,000 美元，此前在上个季度又收购了 119,141 股。Sentinus LLC 在第四季度将其在艾伯维的股份提高了 1.5%。Sentinus LLC 目前拥有 15,788 股该公司的股票，价值为 2,805,000 美元，此前在上个季度又收购了 239 股。最后，多伦多道明银行在第四季度将其在艾伯维的股份提高了 10.4%。多伦多道明银行目前拥有 770,392 股该公司的股票，价值为 136,896,000 美元，此前在上个季度又收购了 72,515 股。70.23% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>分析师评级调整</h2>
<p>几位股票研究分析师最近对该股票发表了评论。美国银行在 6 月 9 日的研究报告中将艾伯维的股票目标价上调至 204.00 美元，并给予该股票 “持有” 评级。华尔街 Zen 在 5 月 22 日的研究报告中将艾伯维的股票评级从 “强力买入” 下调至 “买入”。古根海姆在 8 月 1 日的研究报告中将艾伯维的股票目标价从 216.00 美元上调至 227.00 美元，并给予该股票 “买入” 评级。大和美国在 8 月 7 日的研究报告中将艾伯维的股票评级从 “持有” 上调至 “强力买入”。最后，大和资本市场在 8 月 7 日的研究报告中将艾伯维的股票评级从 “中性” 上调至 “跑赢大盘”，并设定了 214.00 美元的目标价。四位投资分析师对该股票给予了 “强力买入” 评级，十六位给予了 “买入” 评级，六位给予了 “持有” 评级。根据 MarketBeat.com 的数据，艾伯维目前的共识评级为 “适度买入”，共识目标价为 217.10 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p><strong>阅读我们关于 ABBV 的最新研究报告</strong></p>
<h2>内部交易活动</h2>
<p>在其他消息中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股艾伯维股票。该股票以平均价格 198.42 美元出售，总价值为 8,407,055.40 美元。出售后，该执行副总裁持有 177,292 股该公司的股票，价值为 35,178,278.64 美元。此次交易使其持股减少了 19.29%。该出售在向证券交易委员会的法律文件中披露，相关信息可通过此超链接访问。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股艾伯维股票。该股票以平均价格 198.51 美元出售，总交易额为 2,639,190.45 美元。出售完成后，该执行副总裁直接持有 58,247 股该公司股票，价值约为 11,562,611.97 美元。此次交易使其持股减少了 18.58%。该出售的披露信息可在此找到。0.25% 的股票由内部人士持有。</p>
<h2>艾伯维股票下跌 0.8%</h2>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>艾伯维（NYSE:ABBV）股票周五开盘价为 218.40 美元。该公司的市值为 3858.2 亿美元，市盈率为 104.00，PEG 比率为 1.42，贝塔值为 0.53。该公司的 50 日简单移动平均线为 200.25 美元，200 日简单移动平均线为 194.52 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务股本比率为 44.14。艾伯维公司 52 周最低价为 163.81 美元，52 周最高价为 221.76 美元。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日发布了其财报。该公司报告本季度每股收益为 2.97 美元，低于共识预期的 3.24 美元（差额为 0.27 美元）。该公司本季度的收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。艾伯维的净利润率为 6.45%，股本回报率为 699.66%。该公司的收入同比增长 6.6%。在去年同期，该公司每股收益为 2.65 美元。整体来看，股票研究分析师预测艾伯维公司今年将发布每股收益 12.31 美元。</p>
<h2>艾伯维宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 11 月 14 日（星期五）支付。10 月 15 日（星期三）登记的股东将获得 1.64 美元的分红。该分红的除息日为 10 月 15 日（星期三）。这代表着每年 6.56 美元的分红和 3.0% 的分红收益率。艾伯维的派息比率目前为 312.38%。</p>
<h2>艾伯维简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，一种用于治疗自身免疫性疾病和肠道贝赫切特病及脓疱性坏死性皮肤病的注射剂；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；以及 Venclexta/Venclyxto，用于治疗血癌。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比艾伯维更好的股票</li>
<li>低市盈率成长股：开启投资机会</li>
<li>乘着奢侈零售浪潮，这三只高端品牌股票值得关注</li>
<li>如何投资科技股及值得考虑的顶尖科技股</li>
<li>华尔街悄然看好这些中国科技巨头</li>
<li>初学者如何阅读股票图表</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
<p>在你考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>财富联盟顾问集团有限公司在第二季度将其在艾伯维公司（NYSE:ABBV）的持股增加了 30.1%，目前持有 13,161 股，价值 244 万美元。其他机构投资者也提高了他们的持仓。分析师对艾伯维的评级不一，普遍评级为 “适度买入”，目标价为 217.10 美元。最近有内部人士出售股票的情况，管理层以约 198.42 美元的价格出售了股份。艾伯维的股票开盘价为 218.40 美元，市值为 3858.2 亿美元，市盈率为 104.00</p>

<p>Wealth Alliance Advisory Group LLC grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 30.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,161 shares of the company's stock after purchasing an additional 3,047 shares during the quarter. Wealth Alliance Advisory Group LLC's holdings in AbbVie were worth $2,443,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>财富联盟顾问集团有限公司在最近向证券交易委员会提交的文件中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股增加了 30.1%。该机构投资者在本季度购买了 3,047 股后，持有该公司 13,161 股股票。财富联盟顾问集团有限公司在艾伯维的持股在最近的报告期末价值为 2,443,000 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Brighton Jones LLC raised its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Siemens Fonds Invest GmbH raised its stake in AbbVie by 197.6% during the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after acquiring an additional 119,141 shares in the last quarter. Sentinus LLC raised its stake in AbbVie by 1.5% during the 4th quarter. Sentinus LLC now owns 15,788 shares of the company's stock worth $2,805,000 after acquiring an additional 239 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in AbbVie by 10.4% during the 4th quarter. Toronto Dominion Bank now owns 770,392 shares of the company's stock worth $136,896,000 after acquiring an additional 72,515 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也买卖了 ABBV 的股票。布莱顿琼斯有限公司在第四季度将其在艾伯维的股份提高了 17.4%。布莱顿琼斯有限公司目前拥有 22,912 股该公司的股票，价值为 4,072,000 美元，此前在上个季度又收购了 3,401 股。Revolve Wealth Partners LLC 在第四季度将其在艾伯维的股份提高了 72.7%。Revolve Wealth Partners LLC 目前拥有 7,279 股该公司的股票，价值为 1,294,000 美元，此前在上个季度又收购了 3,064 股。西门子基金投资有限公司在第四季度将其在艾伯维的股份提高了 197.6%。西门子基金投资有限公司目前拥有 179,440 股该公司的股票，价值为 32,000 美元，此前在上个季度又收购了 119,141 股。Sentinus LLC 在第四季度将其在艾伯维的股份提高了 1.5%。Sentinus LLC 目前拥有 15,788 股该公司的股票，价值为 2,805,000 美元，此前在上个季度又收购了 239 股。最后，多伦多道明银行在第四季度将其在艾伯维的股份提高了 10.4%。多伦多道明银行目前拥有 770,392 股该公司的股票，价值为 136,896,000 美元，此前在上个季度又收购了 72,515 股。70.23% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities research analysts recently commented on the stock. Bank of America lifted their price target on shares of AbbVie to $204.00 and gave the stock a &#34;hold&#34; rating in a research note on Monday, June 9th. Wall Street Zen downgraded shares of AbbVie from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, May 22nd. Guggenheim raised their price objective on shares of AbbVie from $216.00 to $227.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, August 1st. Daiwa America raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 7th. Finally, Daiwa Capital Markets raised shares of AbbVie from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $214.00 price objective on the stock in a research report on Thursday, August 7th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $217.10.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了评论。美国银行在 6 月 9 日的研究报告中将艾伯维的股票目标价上调至 204.00 美元，并给予该股票 “持有” 评级。华尔街 Zen 在 5 月 22 日的研究报告中将艾伯维的股票评级从 “强力买入” 下调至 “买入”。古根海姆在 8 月 1 日的研究报告中将艾伯维的股票目标价从 216.00 美元上调至 227.00 美元，并给予该股票 “买入” 评级。大和美国在 8 月 7 日的研究报告中将艾伯维的股票评级从 “持有” 上调至 “强力买入”。最后，大和资本市场在 8 月 7 日的研究报告中将艾伯维的股票评级从 “中性” 上调至 “跑赢大盘”，并设定了 214.00 美元的目标价。四位投资分析师对该股票给予了 “强力买入” 评级，十六位给予了 “买入” 评级，六位给予了 “持有” 评级。根据 MarketBeat.com 的数据，艾伯维目前的共识评级为 “适度买入”，共识目标价为 217.10 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p><strong>Read Our Latest Research Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ABBV 的最新研究报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares of the company's stock, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. The trade was a 18.58% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股艾伯维股票。该股票以平均价格 198.42 美元出售，总价值为 8,407,055.40 美元。出售后，该执行副总裁持有 177,292 股该公司的股票，价值为 35,178,278.64 美元。此次交易使其持股减少了 19.29%。该出售在向证券交易委员会的法律文件中披露，相关信息可通过此超链接访问。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股艾伯维股票。该股票以平均价格 198.51 美元出售，总交易额为 2,639,190.45 美元。出售完成后，该执行副总裁直接持有 58,247 股该公司股票，价值约为 11,562,611.97 美元。此次交易使其持股减少了 18.58%。该出售的披露信息可在此找到。0.25% 的股票由内部人士持有。</p>
</div><h2>AbbVie Stock Down 0.8%</h2>
<div class="lb-trans"><h2>艾伯维股票下跌 0.8%</h2>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>Shares of NYSE:ABBV opened at $218.40 on Friday. The company has a market cap of $385.82 billion, a price-to-earnings ratio of 104.00, a PEG ratio of 1.42 and a beta of 0.53. The firm's 50-day simple moving average is $200.25 and its 200-day simple moving average is $194.52. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $221.76.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV）股票周五开盘价为 218.40 美元。该公司的市值为 3858.2 亿美元，市盈率为 104.00，PEG 比率为 1.42，贝塔值为 0.53。该公司的 50 日简单移动平均线为 200.25 美元，200 日简单移动平均线为 194.52 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务股本比率为 44.14。艾伯维公司 52 周最低价为 163.81 美元，52 周最高价为 221.76 美元。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.65 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日发布了其财报。该公司报告本季度每股收益为 2.97 美元，低于共识预期的 3.24 美元（差额为 0.27 美元）。该公司本季度的收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。艾伯维的净利润率为 6.45%，股本回报率为 699.66%。该公司的收入同比增长 6.6%。在去年同期，该公司每股收益为 2.65 美元。整体来看，股票研究分析师预测艾伯维公司今年将发布每股收益 12.31 美元。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.0%. AbbVie's payout ratio is presently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 11 月 14 日（星期五）支付。10 月 15 日（星期三）登记的股东将获得 1.64 美元的分红。该分红的除息日为 10 月 15 日（星期三）。这代表着每年 6.56 美元的分红和 3.0% 的分红收益率。艾伯维的派息比率目前为 312.38%。</p>
</div><h2>AbbVie Profile</h2>
<div class="lb-trans"><h2>艾伯维简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，一种用于治疗自身免疫性疾病和肠道贝赫切特病及脓疱性坏死性皮肤病的注射剂；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；以及 Venclexta/Venclyxto，用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比艾伯维更好的股票</li>
<li>低市盈率成长股：开启投资机会</li>
<li>乘着奢侈零售浪潮，这三只高端品牌股票值得关注</li>
<li>如何投资科技股及值得考虑的顶尖科技股</li>
<li>华尔街悄然看好这些中国科技巨头</li>
<li>初学者如何阅读股票图表</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

财富联盟咨询集团 LLC 收购了艾伯维公司 $ABBV 的股票